Predictive clinical biomarkers market could grow 73% to $14.69b by 2030

MarketsandMarkets estimated a CAGR of 11.6% over the five-year period.

The global predictive clinical biomarkers market is forecast to increase to $14.69b by 2030 from $8.49b in 2025, representing a compound annual growth rate (CAGR) of 11.6%, according to a MarketsandMarkets report.

MarketsandMarkets said the market expansion reflects wider use of predictive biomarkers in clinical trials and treatment selection, particularly in oncology and precision medicine applications, where biomarker testing is increasingly embedded in drug development and therapeutic decision-making.

By product type, consumables are expected to account for the largest share of market revenue over the forecast period, whilst PCR-based technologies are projected to remain the dominant testing platform, the report showed. Cancer is expected to remain the largest application segment for predictive clinical biomarkers.

Regionally, North America held the largest share of the predictive clinical biomarkers market in 2024, supported by established diagnostic infrastructure and reimbursement frameworks. Asia-Pacific is expected to record the fastest growth rate through 2030, according to MarketsandMarkets, as investment in diagnostics and precision medicine increases across the region.